CPHRF (Cipher Pharmaceuticals) Research & Development: $0.00 Mil (TTM As of Mar. 2026)


CPHRF Cipher Pharmaceuticals Inc CPHRF
96 GF Score
Price $11.43
GF Value $12.19
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Cipher Pharmaceuticals Research & Development?

Cipher Pharmaceuticals CPHRF 96 Research & Development is $0.00 Mil as of Mar. 2026. GuruFocus rates CPHRF with a GF Score™ of 96/100 and a GF Value™ of $12.19 (Fairly Valued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Cipher Pharmaceuticals's Research & Development for the three months ended in Mar. 2026 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Cipher Pharmaceuticals  (OTCPK:CPHRF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Cipher Pharmaceuticals Research & Development Related Terms

Cipher Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Cipher Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cipher Pharmaceuticals Research & Development Chart

Cipher Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.10 0.14 0.00 0.02

Cipher Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.00 0.00 0.00 0.00
CPHRF
96GF Score
Cipher Pharmaceuticals Inc CPHRF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cipher Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.00 Mil mean?
Cipher Pharmaceuticals (CPHRF) has a Research & Development of $0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Cipher Pharmaceuticals and its competitors.
Is Cipher Pharmaceuticals' Research & Development too high?
Cipher Pharmaceuticals' current Research & Development is $0.00 Mil. Overall, Cipher Pharmaceuticals has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cipher Pharmaceuticals' Research & Development compare to ZTS?
Cipher Pharmaceuticals' Research & Development of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Cipher Pharmaceuticals and its competitors. Cipher Pharmaceuticals's current Research & Development is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipher Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Cipher Pharmaceuticals (CPHRF) is currently considered Fairly Valued. The stock's GF Value™ is $12.19, compared to a current price of $11.43 — trading 6.2% below its estimated fair value. The current Research & Development is $0.00 Mil. Cipher Pharmaceuticals' overall GF Score™ is 96/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Cipher Pharmaceuticals (CPHRF), the current Research & Development is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cipher Pharmaceuticals (CPHRF) Overvalued in 2026?

Based on GuruFocus' analysis, Cipher Pharmaceuticals stock appears to be undervalued. The current stock price of $11.43 is trading 6.2% below its estimated GF Value™ of $12.19. GuruFocus considers Cipher Pharmaceuticals to be Fairly Valued.

Key valuation signals for CPHRF:

  • Research & Development: $0.00 Mil
  • GF Value™: $12.19 vs. price of $11.43 (6.2% below fair value)
  • GF Score™: 96/100 with 5 warning signs

No single metric tells the full story. See the CPHRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cipher Pharmaceuticals Business Description

Other Exchanges PHE:GermanyCPH:Canada
Address 5750 Explorer Drive, Suite 404, Mississauga, ON, CAN, L4W 0A9
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company is building its business through product acquisitions, out-licensing, and in-licensing arrangements. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products, among others. The company's geographical operational areas include Canada and the United States.
96GF Score

Get the complete analysis for CPHRF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.43
Price
$12.19
GF Value